Jazz Pharmaceuticals Shares Surge 30% on Strong Q3 and Cancer Trial Data
Jazz Pharmaceuticals stock jumped nearly 30% following robust third-quarter results and positive clinical trial data for its oncology candidate. The one-month return climbed 14.88%, with shares trading near $189 and a market capitalization around $11.48 billion.
1. Stock Price Surge
Shares of Jazz Pharmaceuticals surged nearly 30%, closing around $189 per share on February 26, 2026.
2. Third-Quarter Performance
The company delivered robust Q3 revenue growth across its sleep disorder, epilepsy and oncology portfolios, beating analyst estimates on sales momentum.
3. Oncology Trial Progress
Positive clinical trial data for Jazz’s lead oncology candidate demonstrated key efficacy endpoints, fueling optimism about its cancer drug pipeline.
4. Valuation and Fund Interest
The stock’s one-month return reached 14.88%, driving market capitalization to approximately $11.48 billion, while hedge fund holdings increased to 64 portfolios at quarter-end.